Ambrx Biopharma Profit Margin 2020-2023 | AMAM

Current and historical gross margin, operating margin and net profit margin for Ambrx Biopharma (AMAM) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Ambrx Biopharma net profit margin as of March 31, 2023 is 0%.
Ambrx Biopharma Annual Profit Margins
Ambrx Biopharma Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.570B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $135.379B 8.27
GSK (GSK) United Kingdom $68.795B 9.60
Bio-Rad Laboratories (BIO.B) United States $11.071B 29.60
QIAGEN (QGEN) Netherlands $10.284B 21.71
Ginkgo Bioworks Holdings (DNA) United States $3.295B 0.00
Arcus Biosciences (RCUS) United States $1.502B 0.00
Biohaven (BHVN) United States $1.195B 0.00
Emergent Biosolutions (EBS) United States $0.430B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.181B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.016B 0.00